Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(38)
•••

Post by stockfyon Nov 14, 2022 5:16am

871 Views

Post# 35095811

CPH: Outperformer, Give Credit When Credit Is Due

I just want to give credit where credit is due. I bought CPH thanks to Value Digger, a veteran fund manager and author from Seeking Alpha and his research. I m one of his subscribers. Value Digger from Seeking Alpha advised the subscribers to his "Value Investor's Stock Club" research to buy CPH at CAD$0.80 per share in 2021:

Value Digger from Seeking Alpha And His Research

CPH currently is at about CAD$3.40, while many other stocks including healthcare stocks have dropped a lot since 2021.

So CPH is an outperformer that has yielded approximately 300% since his BUY recommendation. Enough said.

<< Previous

Bullboard Posts

Next >>

A new NASDAQ listing for a key player in the global critical minerals space